## ILMN: Illumina, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.62 indicates fundamental undervaluation. Quality metrics strong (ROE 31%). Consistent execution (3/4 quarters beat estimates). Caution: momentum weakening (-2.5% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($126.30)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Illumina, Inc. $ILMN Shares Acquired by Aaron Wealth Advisors LLC**
- Source: MarketBeat | 20251218T050959 | Somewhat-Bullish | Relevance: 100%
- Aaron Wealth Advisors LLC significantly increased its stake in Illumina, Inc. (NASDAQ:ILMN) during Q3, acquiring an additional 8,109 shares and bringing their total holdings to 10,476 shares valued at approximately $995,000. This comes as Illumina exceeded Q3 earnings expectations with an EPS of $1.34 and reaffirmed its FY2025 guidance. Despite diverse institutional investor activity and recent insider transactions, market consensus currently rates Illumina as a "Hold" with an average price target of $117.19.

**2. Scott Davies Sells 323 Shares of Illumina (NASDAQ:ILMN) Stock**
- Source: MarketBeat | 20251217T060918 | Neutral | Relevance: 100%
- Illumina insider Scott Davies sold 323 shares of the company's stock on December 12th at an average price of $136.09, totaling $43,957.07, reducing his stake by 1.77%. Despite the insider sale, Illumina recently traded near $131.56 after exceeding Q3 earnings estimates and providing strong FY2025 guidance. The company holds an average analyst rating of "Hold" with a target price of approximately $117.19, and institutional investors have been actively adjusting their positions.

**3. “It can’t wait until tomorrow”: How patient advocacy drives change**
- Source: Illumina | 20251218T150959 | Bullish | Relevance: 100%
- Illumina's Patient Advocacy Team, composed of Shirlene Badger, Cody Barnett, and Sergio Diaz, is dedicated to making genomics accessible to patients and families. They emphasize that access to genomic insights is often a matter of life and death, requiring urgent action and long-term strategic collaboration across diverse stakeholders. The team works to bridge the gap between scientific research and community needs, advocating for policy changes and access to genomic testing to transform lives.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Barclays | $110 | $100 | +10% |
| 2025-12-15 | JP Morgan | $130 | $105 | +24% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Barclays | main | Underweight |
| 2025-12-15 | JP Morgan | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.09M) |
| Sells | 10 ($80.38M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 53.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Capital World Invest: 13.1% (+20.0%)
- Blackrock Inc.: 12.2% (-3.5%)
- Vanguard Group Inc: 9.6% (-3.5%)
- State Street Corpora: 3.9% (+6.8%)
- Sessa Capital IM, L.: 3.1% (-0.8%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-2.5% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $80M sold (10 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.62 indicates undervaluation relative to growth. Forward P/E 26.9x stretched relative to 6% growth. Quality metrics strong (ROE 31%, margin 16%). Analyst sentiment positive (2 raises, avg +17%). Insider selling cluster ($80.4M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $20.7B |
| Beta | 1.44 |
| 52W Range | $68.70 - $153.06 |
| Short Interest | 7.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.62 |
| Forward P/E | 26.9 |
| Current P/E | 28.6 |
| YoY Growth | 6.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 5.5% to 3.0% (-2.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 1.0pp (needs >4.0% for momentum thesis). MRS_5 at 0.7% confirms short-term momentum alignment. AM_20 at 3.3% shows strong absolute momentum above own 20MA. Outperforming sector by 3.1pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-0.65), momentum weakening. Elevated volume (1.5x 20MA), institutional activity likely. OFD pattern: +MTH (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 3.00% (CS: 77) | Neutral |
| RSI_14 | 63.8 | Neutral |
| MACD Histogram | -0.65 | Bearish |
| vs SMA20 | 1.033x | Above |
| vs SMA50 | 1.147x | Above |
| vs SMA200 | 1.390x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $134.78
- **Stop Loss:** $126.30 (6.3% risk)
- **Target:** $151.74 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 141
- **Position Value:** $19,003.98
- **Portfolio %:** 19.00%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-05 (Est: $1.23)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.17 | $1.34 | +14.7% |
| 2025Q2 | $1.01 | $1.19 | +17.7% |
| 2025Q1 | $0.94 | $0.97 | +3.3% |
| 2024Q4 | $0.92 | $0.86 | -6.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*